Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

NCT00505700 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00505700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00505700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2003
Completion date
Not reported
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia